Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Thomas Jefferson University
Thomas Jefferson University
University of Chicago
University of Wisconsin, Madison
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Swiss Cancer Institute